Abstract
Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure–activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.
Keywords: Agonist, Ca2+ mobilization, chiral recognition, formyl peptide receptor, G protein-coupled receptor, neutrophil, molecular modeling.
Current Medicinal Chemistry
Title:Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition
Volume: 21 Issue: 13
Author(s): I.A. Schepetkin, A.I. Khlebnikov, M.P. Giovannoni, L.N. Kirpotina, A. Cilibrizzi and M.T. Quinn
Affiliation:
Keywords: Agonist, Ca2+ mobilization, chiral recognition, formyl peptide receptor, G protein-coupled receptor, neutrophil, molecular modeling.
Abstract: Formyl peptide receptors (FPRs) are G protein-coupled receptors (GPCRs) expressed on a variety of cell types. These receptors play an important role in the regulation of inflammatory reactions and sensing cellular damage. They have also been implicated in the pathogenesis of various diseases, including neurodegenerative diseases, cataract formation, and atherogenesis. Thus, FPR ligands, both agonists and antagonists, may represent novel therapeutics for modulating host defense and innate immunity. A variety of molecules have been identified as receptor subtype-selective and mixed FPR agonists with potential therapeutic value during last decade. This review describes our efforts along with recent advances in the identification, optimization, biological evaluation, and structure–activity relationship (SAR) analysis of small molecule non-peptide FPR agonists and antagonists, including chiral molecules. Questions regarding the interaction at the molecular level of benzimidazoles, pyrazolones, pyridazin-3(2H)-ones, N-phenylureas and other derivatives with FPR1 and FPR2 are discussed. Application of computational models for virtual screening and design of FPR ligands is also considered.
Export Options
About this article
Cite this article as:
Schepetkin I.A., Khlebnikov A.I., Giovannoni M.P., Kirpotina L.N., Cilibrizzi A. and Quinn M.T., Development of Small Molecule Non-peptide Formyl Peptide Receptor (FPR) Ligands and Molecular Modeling of Their Recognition , Current Medicinal Chemistry 2014; 21(13) . https://dx.doi.org/10.2174/0929867321666131218095521
DOI https://dx.doi.org/10.2174/0929867321666131218095521 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Editorial Policies
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Allegations from Whistleblowers
- Publishing Ethics and Rectitude
- Increase Visibility Of Your Article
- Archiving Policies
- Reviewer Guidelines
- Guest Editor Guidelines
- Board Recruitment Workflow
- Short Guide for New Editors
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Announcements
- Forthcoming Thematic Issues
Related Articles
-
Members of CRF Family and their Receptors: From Past to Future
Current Medicinal Chemistry Revisiting the J-curve Phenomenon. An Old New Concept?
Current Hypertension Reviews Attenuation of Hydroxyl Radical Formation by Extracted Constituent of Moringa oleifera Lam
Current Chemical Biology Resurgence of Herbal Antihypertensives in Management of Hypertension
Current Hypertension Reviews Neurogenesis and Sensorimotor Gating: Bridging a Microphenotype and an Endophenotype
Current Molecular Medicine Recent Advances of Calcium Phosphate Nanoparticles for Controlled Drug Delivery
Mini-Reviews in Medicinal Chemistry The Perfect Storm: A Rheumatologist's Point of View on COVID-19 Infection
Current Rheumatology Reviews New Antipsychotics and Schizophrenia: A Review on Efficacy and Side Effects
Current Medicinal Chemistry Renal Complications of Fabry Disease
Current Pharmaceutical Design Characterization and Antihypertensive Effect of the Complex of (-)-β- pinene in β-cyclodextrin
Current Pharmaceutical Biotechnology Molecular Mechanisms of Biological Activity of Oleanolic Acid - A Source of Inspiration for A New Drugs Design
Mini-Reviews in Organic Chemistry New Targets for Treating the Underlying Pathophysiology and Nonmotor Aspects of Parkinson's Disease
CNS & Neurological Disorders - Drug Targets Fish Hydrolysates: A Regulatory Perspective of Bioactive Peptides
Protein & Peptide Letters Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety PPAR Ligands Containing Stilbene Scaffold
Mini-Reviews in Medicinal Chemistry Cold-induced Anaphylaxis: The Case of a 9-year-old Child and Review of the Literature
Endocrine, Metabolic & Immune Disorders - Drug Targets The Role of Cnidaria in Drug Discovery. A Review on CNS Implications and New Perspectives
Recent Patents on CNS Drug Discovery (Discontinued) The Renin-Angiotensin System: The Role of Inhibitors, Blockers, and Genetic Polymorphisms in the Treatment and Prevention of Heart Failure
Current Vascular Pharmacology Participation of the Cannabinoid System in the Regulation of Emotional- Like Behaviour
Current Pharmaceutical Design The History and Rationale for Monoclonal Antibodies in the Treatment of Hematologic Malignancy
Current Pharmaceutical Biotechnology